ONC panel addresses MU criticism

CHICAGO—A panel of leaders from the Office of the National Coordinator for Health IT (ONC) shared their recent accomplishments and future plans while diplomatically fielding questions about criticisms of the just-released Meaningful Use (MU) Stage 3 proposed rule.

The proposed rule includes a change in the measure of a 5 percent threshold of patients using view, download and transmit capabilities to requiring just one patient doing so during each reporting year. Athenahealth’s Jonathan Bush called the move the “dumbing down” of the MU program but when pressed, National Coordinator Karen DeSalvo, MD, MPH, MSc, simply said, “Our commitment to consumers and consumer health information is unwavering.”

Jodi Daniel, JD, MOH, director of ONC’s Office of Policy, was quick to point out that VDT capability is still required for EHR certification. The only change is whether or not patients actually do it.

DeSalvo also said the proposed rule has led to great dialogue. “We want to bring people to the table. This is the time for comment. This is much more than technology. There are so many great stories about how people access their information. When it starts to work, it works great.” She also said they remain focused on outcomes but are thinking through the tools and cultural change that will bring everybody in.

ONC’s Chief Privacy Officer Lucia Savage, JD, said the dialogue between providers and patients is ongoing. “We want to foster trust so the information goes where it needs to go.”

When asked about the information blocking report ONC released last week, DeSalvo said it will take action on the part of the federal government along with the existing administrative authority of the private sector to combat the problem. “There may be additional opportunities for Congress to weigh in but she noted the “tremendous amount of advancement in the private sector.”

 

 

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.